Denis Leonardo Fontes Jardim

Present Title & Affiliation

• Associate Senior Oncologist and National Head of Genitourinary Tumors, Oncoclínicas & Co Oncology Group, Brazil
• PhD Professor of Medical Sciences, Hospital Sírio-Libanês, São Paulo, Brazil

RESEARCH ACTIVITIES

1. 2001–2006 – Research Fellow Program
Supervisor: Fernando Ferreira Costa, MD, PhD
Department of Hematology and Hemotherapy, University of Campinas, Brazil

• Described and characterized the Sar1b human gene during erythropoiesis.

2. Fall 2010 – Research Trainee
Supervisor: Toni K. Choueiri, MD
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

• Conducted research on hematologic toxicities associated with bevacizumab in cancer patients.

3. 2011–2014 – PhD in Hematology and Oncology
Supervisor: Fernando Ferreira Costa, MD, PhD
University of Campinas, Brazil

• Investigated the effects of silencing the Sar1b gene by RNA interference during erythropoiesis.
• Assessed the predictive value of Phase I clinical trials for safety and optimal dosing in registration studies.
• Analyzed the impact of personalized therapy strategies in the drug development process.

4. 2012–2014 – Clinical Research and Phase I Trials
Supervisor: David S. Hong, MD
Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX

• Authored and led the Phase I clinical trial evaluating the combination of Dasatinib and Crizotinib in patients with advanced cancers (NCT01744652, active and recruiting).

5. 2013–Present – Principal Investigator, Hospital Sírio-Libanês / ICESP
Ongoing leadership in translational and clinical oncology trials:

• In vitro modulation of dendritic cells from cancer patients with Rb9 peptide.
  Sponsor: Recepta Biopharma
• Phase III study of MPDL3280A (Anti–PD-L1 antibody) in advanced urothelial bladder cancer after platinum failure.
  Sponsor: Roche
• CA045-009 (MIBC): Phase III trial of nivolumab + bempegaldesleukin (NKTR-214) versus nivolumab alone versus standard of care in cisplatin-ineligible muscle-invasive bladder cancer.
  Sponsor: Bristol Myers Squibb (BMS)
• Erdafitinib study in advanced solid tumors with FGFR gene alterations.
  Sponsor: Janssen
• TAPISTRY Platform Study: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You.
  Sponsor: Janssen
• Apalutamide + Radiotherapy + LHRH Agonist study in high-risk PSMA-PET–positive hormone-sensitive prostate cancer, including observational follow-up for PSMA-PET–negative patients.
  Sponsor: Janssen

6. Co-Principal Investigator (Co-PI) Studies
Collaborative clinical investigations in prostate and bladder cancer:

• Neoadjuvant androgen deprivation therapy + abiraterone ± apalutamide for high-risk prostate cancer.
  Sponsor: Janssen
• Low-dose abiraterone with food in metastatic castration-resistant prostate cancer (mCRPC).
  Sponsor: Hospital Sírio-Libanês
• CheckMate 9KD: Evaluation of nivolumab-based checkpoint inhibition in prostate cancer.
  Sponsor: Bristol Myers Squibb
• THOR-2 trial: Erdafitinib vs. intravesical chemotherapy in BCG-refractory high-risk NMIBC.
  Sponsor: Janssen

VI. ONGOING PROJECTS AND SUPERVISIONS

Dr. Denis Leonardo Fontes Jardim currently leads and supervises several research and clinical projects that span translational oncology, clinical trial innovation, and biomarker discovery.

1. PhD Supervision – Frederico Leal
   Project: Urinary microbiome as a biomarker for renal cell carcinoma
   This doctoral project, conducted at Hospital Sírio-Libanês, explores the relationship between the urinary microbiome and renal cell carcinoma, aiming to identify microbial signatures that could serve as diagnostic or prognostic biomarkers.
2. PhD Supervision – Camila Bragança
   Project: Determinants of tumor mutational burden (TMB) as a biomarker for solid tumors
   Based at Hospital Sírio-Libanês, this study investigates molecular and genomic factors that influence TMB levels and their potential role in predicting response to immunotherapy across different tumor types.
3. Research Project – Principal Investigator
   Project: Artificial Intelligence as a biomarker in patients with prostate cancer treated during the LACOG-0415 clinical trial
   Conducted under the LACOG-GU network, this project integrates AI-driven analytical models to assess treatment outcomes and predict disease progression in prostate cancer.
4. Clinical Trial Proposal – Principal Investigator
   Project: Fezolinetant for the treatment of vasomotor symptoms related to androgen deprivation therapy (ADT) in prostate cancer (The FEZO-PRO Trial)
   Developed within LACOG-GU, this proposed study evaluates Fezolinetant as a novel therapeutic option for alleviating vasomotor symptoms associated with ADT in prostate cancer patients.
5. Clinical Trial – Principal Investigator
   Project: Salvage Artificial Intelligence Predictive Model (ArteraAI) for Salvage Radiation Strategy Decision (SMART)
   In collaboration with LACOG-GU, this ongoing trial utilizes AI-based predictive modeling (ArteraAI) to optimize radiation therapy decision-making in the salvage setting for prostate cancer.

 

PEER-REVIEW PUBLICATIONS

1. Jardim DL, da Cunha AF, Costa FF. Molecular Cloning and Expression Study of the Sar1a Human Gene During Erythropoiesis. Brazilian Journal of Hematology and Hemotherapy. August 2003; 25(Suppl 2):43.

2. Jardim DL, da Cunha AF, Duarte Ada S, dos Santos CO, Saad ST, Costa FF. Expression of Sara2 Human Gene in Erythroid Progenitors. J Biochem Mol Biol. 2005 May 31;38(3):328–333.

3. Jardim DL, Calabrich AFC, Katz A. Determining the Frequency of CYP2D6 Polymorphisms in Brazilian Women and Literature Review. Rev Bras Mastol. 2010; 20:15–21.

4. Souza CE, Bastos DA, Jardim DL, Martins SC, Laporti R, Maluf FC. A Phase I Open-Label Study of Escalating-Dose Oral Cyclophosphamide, Docetaxel, Zoledronic Acid, and High-Dose Calcitriol for Castration-Resistant Prostate Cancer.J Clin Oncol. 2010;28(Suppl):e15079.

5. Schutz FA, Jardim DL, Je Y, Choueiri TK. Hematologic Toxicities Associated with the Addition of Bevacizumab in Cancer Patients. Eur J Cancer. 2011 May;47(8):1161–1174.

6. Jardim DL, Angerami RN, Tsukumo DM, Carvalho-Filho MA, Saad MJA. Autoimmune Features Caused by Dengue Fever: A Case Report. Braz J Infect Dis. 2012;16(1).

7. Jardim DL, Rodrigues CA, Novis YA, Rocha VG, Hoff PM. Oxaliplatin-Related Thrombocytopenia. Ann Oncol. 2012 Aug;23(8):1937–1942.

8. Jardim DL, Gagliato DM, Ribeiro KB, Shimada AK, Katz A. Bevacizumab as First-Line Therapy in Advanced Non–Small Cell Lung Cancer: A Brazilian Center Experience. Drugs R D. 2012 Dec 1;12(4):207–216.

9. Jardim DL, Conley A, Subbiah V. Comprehensive Characterization of Malignant Phyllodes Tumor by Whole Genomic and Proteomic Analysis: Biological Implications for Targeted Therapy Opportunities. Orphanet J Rare Dis. 2013 Jul 30;8(1):112.

10. Jardim DL, Hess KR, LoRusso P, Kurzrock R, Hong DS. Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs. Clin Cancer Res. 2014 Jan 15;20(2):281–288.

11. Jardim DL, Wheler JJ, Hess K, et al. FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS One. 2014 Feb 19;9(2):e89388.

12. Tang C, Jardim DL, Falchook GS, et al. MET Nucleotide Variations and Amplification in Advanced Ovarian Cancer: Characteristics and Outcomes with c-MET Inhibitors. Oncoscience. 2014;1(1):5.

13. Tang C, Jardim DL, Hong D. MET in Ovarian Cancer: Metastasis and Resistance? Cell Cycle. 2014 Apr 15;13(8):1220–1221.

14. Jardim DL, de Melo Gagliato D, Falchook GS, et al. MET Aberrations and c-MET Inhibitors in Patients with Gastric and Esophageal Cancers in a Phase I Unit. Oncotarget. 2014 Apr 15;5(7):1837–1845.

15. Donnard E, Asprino PF, Correa BR, et al. Mutational Analysis of Genes Coding for Cell Surface Proteins in Colorectal Cancer Cell Lines Reveals Novel Altered Pathways and Druggable Mutations. Oncotarget. 2014 Oct 15;5(19):9199–9213.

16. de Melo Gagliato D, Jardim DL, Falchook GS, et al. Analysis of MET Genetic Aberrations in Patients with Breast Cancer at the MD Anderson Phase I Unit. Clin Breast Cancer. 2014 Dec;14(6):468–474.

17. Tang C, Hess K, Jardim DL, et al. Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic. Clin Cancer Res. 2014 Dec 1;20(23):5956–5963.

18. Jardim DL, Tang C, Gagliato DM, et al. Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15;20(24):6336–6345.

19. Jardim DL, de Melo Gagliato D, Falchook GS, et al. MET Abnormalities in Patients with Genitourinary Malignancies and Outcomes with c-MET Inhibitors. Clin Genitourin Cancer. 2015 Feb;13(1):e19–e26.

20. Toloi DA, Jardim DL, Hoff PM, Riechelmann RS. Phase I Trials of Antitumor Agents: Fundamental Concepts.Ecancermedicalscience. 2015 Jan 19;9:501.

21. Jardim DL, Schwaederle M, Wei C, et al. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-Analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Sep 15;107(11).

22. Gagliato DM, Jardim DL, Marchesi MS, Hortobagyi GN. Mechanisms of Resistance and Sensitivity to Anti-HER2 Therapies in HER2+ Breast Cancer. Oncotarget. 2016 Jan 27.

23. Jardim DL, Gagliato DM. Recent Results of Immunotherapy and Perspectives for Advanced NSCLC. Lung Cancer Management. 2016;5(2):57–60.

24. Jardim DL, Schwaederle M, Hong DS, Kurzrock R. An Appraisal of Drug Development Timelines in the Era of Precision Oncology. Oncotarget. 2016 Jul 13.

25. Jardim DL, Groves ES, Breitfeld PP, Kurzrock R. Factors Associated with Failure of Oncology Drugs in Late-Stage Clinical Development: A Systematic Review. Cancer Treat Rev. 2016 Nov 4;52:12–21.

26. Bugano DDG, Hess K, Jardim DL, et al. Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs. Clin Cancer Res. 2017 Aug 1;23(15):4020–4026.

27. Kato S, Jardim DL, Johnson FM, et al. Phase I Study of the Combination of Crizotinib and Dasatinib in Patients with Advanced Cancer. Invest New Drugs. 2018 Jun;36(3):416–423.

28. Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R. Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. Clin Cancer Res. 2018 Apr 15;24(8):1785–1794.

29. de Melo Gagliato D, Jardim DL. Noninvasive Cancer Biomarkers in Solid Malignancies: Circulating Tumor DNA—Clinical Utility, Current Limitations, and Future Perspectives. Ann Transl Med. 2018 Jun;6(11):233.

30. Jardim DL, de Melo Gagliato D, Kurzrock R. Lessons from the Development of the Immune Checkpoint Inhibitors in Oncology. Integr Cancer Ther. 2018 Dec;17(4):1012–1015.

31. Millis SZ, Jardim DL, Albacker L, et al. Phosphatidylinositol 3-Kinase Pathway Genomic Alterations in 60,991 Diverse Solid Tumors Inform Targeted Therapy Opportunities. Cancer. 2018 Dec 24.

32. Knebel FH, Bettoni F, da Fonseca LG, Camargo AA, Sabbaga J, Jardim DL. Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer. Front Oncol. 2019 Mar 22;9:170.

33. de Cássio Zequi S, da Costa WH, Korkes F, et al.; Latin American Cooperative Group-GU and Latin American Renal Cancer Group. Renal Cell Cancer Treatment: Expert Panel Recommendations with Focus on Surgery. Ther Adv Urol.2019 Sep 9;11.

34. Lara Gongora AB, Carvalho Oliveira LJ, Jardim DL. Impact of the Biomarker Enrichment Strategy in Drug Development. Expert Rev Mol Diagn. 2020 Jun;20(6):611–618.

35. Soares A, Monteiro FSM, Maluf FC, Bastos DA, Jardim DL, Sasse AD, Gonçalves E Silva A, Fay AP, da Rosa DAR, Wierman E, Kater F, Schutz FA, de Oliveira FNG, Morbeck IAP, Rinck JA Jr, da Trindade KM, Maia MC, Souza VC, da Silva Neto DCV, de Almeida E Paula F, Korkes F, Carvalhal GF, Nogueira L, de Carvalho Fernandes R, Dos Reis RB, Matheus WE, Busato WFS Jr, da Costa WH, de Cássio Zequi S. Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG). J Cancer Res Clin Oncol. 2020 Jul;146(7):1829-1845.

36. Oliveira LJC, Gongora ABL, Jardim DLF. Spectrum and clinical activity of PD-1/PD-L1 inhibitors: regulatory approval and under development. Curr Oncol Rep. 2020 Jun 12;22(7):70.

37. Harada G, Antonacio FF, Gongora AB, Behar MH, Capareli FC, Bastos DA, Munhoz RR, Costa FP, Jardim DL, Arrais-Rodrigues C, Novis Y, Katz A, de Castro Junior G. SARS-CoV-2 testing for asymptomatic adult cancer patients before initiating systemic treatments: a systematic review. Ecancermedicalscience. 2020 Sep 9;14:1100.

38. Jardim DL, Millis SZ, Ross JS, Woo MS, Ali SM, Kurzrock R. Cyclin pathway genomic alterations across 190,247 solid tumors: leveraging large-scale data to inform therapeutic directions. Oncologist. 2021 Jan;26(1):e78-e89.

39. Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021 Feb 8;39(2):154-173.

40. Xavier CB, Marchetti KR, Castria TB, Jardim DLF, Fernandes GS. Trametinib and hydroxychloroquine combination treatment in KRAS-mutated advanced pancreatic adenocarcinoma: detailed description of two cases. J Gastrointest Cancer. 2021 Mar;52(1):374-380.

41. Maluf F, Soares A, Avanço G, Hada AL, Cardoso APG, Carneiro A, Herchenhorn D, Jardim DLF, Schutz FA, Kater FR, Pereira FMT, Monteiro FSM, Morbeck IAP, Reolon JFN, da Trindade KM, Andrade LMQDS, Nogueira LM, Furoni R, Natel RA, Dos Reis RB, Fogace RN, Souza VC. Consensus on diagnosis and management of non-metastatic castration-resistant prostate cancer in Brazil. Int Braz J Urol. 2021 Mar-Apr;47(2):359-373.

42. Jardim DL, Millis SZ, Ross JS, Woo MS, Ali SM, Kurzrock R. Landscape of cyclin pathway genomic alterations across 5,356 prostate cancers: implications for targeted therapeutics. Oncologist. 2021 Apr;26(4):e715-e718.

43. Engel Ayer Botrel T, Datz Abadi M, Chabrol Haas L, da Veiga CRP, de Vasconcelos Ferreira D, Jardim DL. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number-needed-to-treat analysis from the Brazilian private perspective. J Med Econ.2021;24(1):291-298.

44. Maluf FC, Pereira FMT, Silva AG, Dettino ALA, Cardoso APG, Sasse AS, Soares A, Kann AG, Herchenhorn D, Jardim DLF, Cortés DEL, Kater FR, Morbeck IAP, Reolon JFN, Rinck JA Jr, Zarbá JJ, Sade JP, da Trindade KM, Costa LAGA, Dos Santos LV, Maia MC, Siqueira MB, Gillessen S. Consensus on the treatment and follow-up for metastatic castration-resistant prostate cancer: a report from the first global prostate cancer consensus conference for developing countries (PCCCDC). JCO Glob Oncol. 2021 Apr;7:559-571.

45. Pereira FMT, Silva AGE, Dettino ALA, Cardoso APG, Sasse AD, Kann AG, Dzik C, Herchenhorn D, Jardim DLF, Lopera D, Ayadi M, Salman P, Kopp RAM, De Carvalho RS, Cavallero SRA, Aguiar S, Souza VC, Uson Junior PLS, Soares A. Consensus on the treatment and follow-up for the nonmetastatic castration-resistant prostate cancer: a report from the first prostate cancer consensus conference for developing countries. JCO Glob Oncol. 2021 Apr;7:545-549.

46. Lara Gongora AB, Werutsky G, Jardim DL, Nogueira-Rodrigues A, Barrios CH, Mathias C, Maluf F, Riechelmann R, Fraga M, Gomes H, William WN, Yamada CAF, de Castro G Jr, Rosa DD, de Melo AC, Sala R, Bustamante E, Bretel D, Arrieta O, Cardona AF, Bastos DA. Impact of the COVID-19 pandemic on oncology clinical research in Latin America (LACOG 0420). JCO Glob Oncol. 2021 Apr;7:649-658.

47. Sandoval RL, Masotti C, de Macedo MP, Ribeiro MFSA, Leite ACR, Meireles SI, Bovolin RM, Santini FC, Munhoz RR, Jardim DLF, Katz A, Camargo AA, Fernandes GDS, Achatz MI. Identification of the TP53 p.R337H variant in tumor genomic profiling should prompt consideration of germline testing for Li-Fraumeni syndrome. JCO Glob Oncol. 2021 Jul;7:1141-1150.

48. Xavier CB, Lopes CDH, Harada G, Peres EDB, Katz A, Jardim DL. Cardiovascular toxicity following immune checkpoint inhibitors: a systematic review and meta-analysis. Transl Oncol. 2022 May;19:101383.

49. Heidrich V, Inoue LT, Asprino PF, Bettoni F, Mariotti ACH, Bastos DA, Jardim DLF, Arap MA, Camargo AA. Choice of 16S ribosomal RNA primers impacts male urinary microbiota profiling. Front Cell Infect Microbiol. 2022 Apr 21;12:862338.

50. Jardim DLF, Millis SZ, Ross JS, Lippman S, Ali SM, Kurzrock R. Comprehensive landscape of cyclin pathway gene alterations and co-occurrence with FGF/FGFR aberrations across urinary tract tumors. Oncologist. 2023 Feb 8;28(2):e82-e91.

51. Jardim DL, Gonçalves E Silva A, Pompeo ASFL, et al. Non-metastatic, castration-resistant prostate cancer: diagnostic and treatment recommendations by an expert panel from Brazil. Clin Genitourin Cancer. 2023 Apr;21(2):e58-e69.

52. Xavier CB, Lopes CDH, Awni BM, Campos EF, Alves JPB, Camargo AA, Guardia GDA, Galante PAF, Jardim DL. Interplay between tumor mutational burden and mutational profile and its effect on overall survival: a pilot study of metastatic patients treated with immune checkpoint inhibitors. Cancers (Basel). 2022 Nov 4;14(21):5433.

53. Bastos DA, Gongora ABL, Dzik C, Jardim DL, et al. Multicenter database of patients with germ-cell tumors: a Latin American Cooperative Oncology Group registry (LACOG 0515). Clin Genitourin Cancer. 2023 Jun;21(3):e104-e113.

54. Lima NF Jr, Sampaio LAF, Xavier CB, Mattedi RL, Queiroz MA, Nahas WC, Jardim DL. Complete response to sequential HER2-targeted strategies in a heavily pretreated patient with HER2-amplified metastatic bladder cancer. JCO Precis Oncol. 2023 Jan;7:e2200414.

55. Jardim DL, Murugesan K, Elvin JA, Huang RSP, Kurzrock R. PD-L1 gene amplification and focality: relationship with protein expression. J Immunother Cancer. 2023 Feb;11(2):e006311.

56. Pant S, Schuler M, Iyer G, et al.; RAGNAR Investigators. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 2023 Aug;24(8):925-935.

57. Lopes CDH, Antonacio FF, Moraes PMG, Asprino PF, Galante PAF, Jardim DL, et al. Clinical and molecular profile of lung cancer patients harboring the TP53R337H germline variant in a Brazilian cancer center: possible mechanism of carcinogenesis. Int J Mol Sci. 2023 Oct 10;24(20):15035.

58. Mariotti ACH, Heidrich V, Inoue LT, et al. Urinary microbiota is associated with clinicopathological features in benign prostatic hyperplasia. Prostate. 2024 Feb;84(3):285-291.

59. Heidrich V, Mariotti ACH, Inoue LT, et al. The bladder microbiota is not significantly altered by intravesical BCG therapy. Urol Oncol. 2024 Jan;42(1):22.e13-22.e21.

60. Soares A, … Jardim DL, Bastos DA, Rosa DR, Schutz FA, et al. Advanced renal cell carcinoma management: the LACOG and LARCG consensus update. J Cancer Res Clin Oncol. 2024 Apr 9;150(4):183.

61. Felício de Campos E, Xavier CB, Queiroz MM, Firmino Lima Júnior N, Ilario EN, Coelho RF, Nahas WC, Bastos DA, Fontes Jardim DL. Cardiovascular and thromboembolic events in patients with localized prostate cancer receiving intensified neoadjuvant androgen deprivation: a systematic review and meta-analysis. Clin Genitourin Cancer. 2024 Apr 5;22(3):102088.

62. Bragança Xavier C, Guardia GDA, Alves JPB, Lopes CDH, Awni BM, Campos EF, Jardim DL, Galante PAF. Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitors. Oncologist. 2025 Apr 4;30(4):oyaf078.

63. Lima MZT, Bastos DA, Mattedi RL, Dzik C, Jardim DLF, Coelho R, Ribeiro-Filho LA, Cordeiro MD, Nahas WC, Mello ES, Amano MT, Inoue LT, Camargo AA. Infiltrating natural killer cells influence the efficacy of BCG immunotherapy in non-muscle-invasive bladder cancer. Pathol Res Pract. 2025 Jun;270:155997.

 BOOK CHAPTERS

• 2010 – Gynecologic Cancer
  Multimodal Treatment of IIB–IVA Carcinoma of the Cervix
  Authors: Jardim D.L.F., Calabrich A.F.C.
  Editors: Maluf F.C., Souza C.E., Saragiotto D.F., Capareli F.
  Publisher: Dendrix, 1st edition
• 2011 – Textbook of Otorhinolaryngology
  Chemotherapy and Radiotherapy in Head and Neck Cancer
  Authors: Jardim D.L.F., Monteiro F.S.M., Maluf F.C.
  Editors: Imamura R., Miziara I.D., Eckley C.A., Sih T.M.
  Publisher: Roca, 2nd edition
• 2011 – Tratado de Oncologia
  Alkylating Agents — Jardim D.L.F., Bastos D.A.
  Platinum Compounds — Bastos D.A., Jardim D.L.F.
  Treatment of Early Breast Cancer — Barros A.C.S.D., Katz A., Jardim D.L.F., Bastos D.A., Martella E., Marta G.N., Peixoto R.D.
  Editor: Hoff P.M.G.
  Publisher: Atheneu, 1st edition
• 2014 – Clinical Oncology: Evidence-Based Treatment
  Treatment of Renal, Bladder, Prostate, and Testicular Cancer
  Authors: Jardim D.L.F., Dzik C., de Souza C., Medeiros R., Bastos D.A.
  Editors: Hoff P.M.G. et al.
  Publisher: Sírio-Libanês Hospital, 2nd edition
• 2016 – Manual of Oncology: Rare Tumors
  Small Cell Carcinoma of the Prostate, Urachal Adenocarcinoma, and Bladder Sarcoma
  Author: Jardim D.L.F.
  Editors: Peixoto R.D. et al.
• 2018 – Testicular Cancer Guidelines
  Authors: Jardim D.L.F., Bastos D.A., Rodrigues D., Carcano F., Coelho R., Carrera V., Rinck J.A. Jr.
  Publisher: Brazilian Society of Clinical Oncology (SBOC)
• 2019 – Biomarkers in Oncology
  PI3-Kinase Alterations in Cancer
  Authors: Oliveira L.J., Jardim D.L.F.
  Editors: Costa M.A. et al.
  Publisher: Manole

RESEARCH PRESENTED AT CONFERENCES

2003

• “Molecular Cloning and Expression Study of the Sar1a Human Gene During Erythropoiesis” — Oral presentation at the Brazilian Congress of Hematology and Hemotherapy, São Paulo, Brazil.
• “Molecular Cloning and Expression Study of the Sar1a Human Gene During Erythropoiesis” — Poster presentation at the 49th National Congress of Genetics, Águas de Lindóia, Brazil.

2004

• “Study of Death from Cervical Cancer as a Sentinel Event in the Area of the Health Center DIC III” — Oral presentation at the XIV UNICAMP Academic Medical Congress, Campinas, Brazil (October 2004).

2006

• “Effects of Gene Suppression of Sara2 Human Gene by RNA Interference in K562 Cells” — Oral presentation at the XV UNICAMP Academic Medical Congress, Campinas, Brazil (October 2006).

2009

• “Determining the Frequency of CYP2D6 Polymorphisms in Brazilian Women from Sírio-Libanês Hospital” — Oral presentation at the XVI Brazilian Congress of Clinical Oncology, Fortaleza, Brazil (October 2009).

2011

• “Hematologic Toxicities in Renal Cell Carcinoma and Other Malignancies Treated with Bevacizumab: A Meta-Analysis of Clinical Trials” — Poster presentation at the ASCO Genitourinary Cancers Symposium, Orlando, FL, USA (February 2011).
• “Bevacizumab for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer: Experience from Sírio-Libanês Hospital” — Poster presentation at the XVII Brazilian Congress of Clinical Oncology, Gramado, Brazil (October 2011).

2013

• “Predictive Value of Phase I Trials for Safety and Final Approved Dose in Later Trials: Analysis of 33,845 Patients” — Oral presentation at the ASCO Annual Meeting, Chicago, IL, USA (June 2013).

2014

• “c-MET Abnormalities in Patients with Genitourinary Malignancies and Outcomes with c-MET Inhibitors” — Poster presentation at the Genitourinary Cancers Symposium, San Francisco, CA, USA (February 2014).
• “Systematic Review of a Personalized Strategy in Cancer Clinical Trials Leading to FDA Approval” — Poster presentation at the ASCO Annual Meeting, Chicago, IL, USA (June 2014).

2020

• “Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers” — Poster presentation at the Genitourinary Cancers Symposium, San Francisco, CA, USA (February 2020).
• “Landscape of Cyclin Pathway Genomic Alterations Across 7,207 Non-Prostate Genitourinary Tumors” — Poster presentation at the Genitourinary Cancers Symposium, San Francisco, CA, USA (February 2020).

2021

• “The Value of TMB for Selection of PD-1/PD-L1 Inhibitors” — Oral presentation and session chair at the ESMO Immuno-Oncology Congress (Virtual Meeting) (2021).

2023

• “Thromboembolic Events in Patients with Localized Prostate Cancer Receiving Intensified Neoadjuvant Androgen Deprivation: A Systematic Review and Meta-Analysis” — Poster presentation at the Genitourinary Cancers Symposium, San Francisco, CA, USA (February 2023).

Professional Address: Oncoclínicas – Faria Lima
Avenida Brigadeiro Faria Lima, 4300, 6th Floor, São Paulo-SP, Brazil, ZIP 04538-132
Office Number: +55 11 99707-2594
Email: [email protected]